• J Remon, N Pardo, A Martinez-Martí, S Cedrés, A Navarro, A M Martinez de Castro, and E Felip.
• Hospital Vall d'Hebron, Medical Oncology Department, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. Electronic address: jremon@vhio.net.
• Lung Cancer. 2017 Apr 1; 106: 70-75.

AbstractImmune checkpoint inhibitors are considered standard second-line treatment in advanced non-small cell lung cancer patients. This strategy has also become standard in first-line setting for a subgroup of patients with strongly positive PD-L1 tumors; therefore, PD-L1 status might be considered a new biomarker that deserves upfront testing. New combinations of immune checkpoint inhibitors and with chemotherapy have been tested in first-line treatment. However, some questions remain unanswered such as the best treatment strategy or the real upfront efficacy of these therapeutic strategies in the whole lung cancer population. In this review we summarize the main results in the first-line setting of recent phase III trials with immune checkpoint inhibitors in advanced non-small cell lung cancer patients.Copyright © 2017 Elsevier B.V. All rights reserved.

33 keywords...

hide…